Medicare Negotiations Continue: 15 More Drugs Including Weight-Loss Treatments Could See Price Cuts in 2027

Senior man with grey hair holding pills at the pharmacy with angry face – Shutterstock

Prescription drug costs continue to be one of the biggest financial pressures facing retirees and older Americans. In fact, many Medicare beneficiaries (around 21%) spend more than $1,000 every year on medications for diabetes, cancer, heart disease, arthritis, and obesity. Now, Medicare drug negotiations are entering another major phase, with 15 additional medications expected to receive negotiated lower prices beginning in 2027. The latest list includes several blockbuster GLP-1 medications such as Ozempic, Wegovy, and Rybelsus, which have become some of the most talked-about weight-loss and diabetes treatments in the country.

Medicare Drug Negotiations Are Expanding Rapidly

The Medicare drug negotiations were created through the Inflation Reduction Act, which finally gave Medicare the authority to negotiate prices directly with pharmaceutical companies for certain high-cost drugs. The first round involved 10 medications whose lower prices took effect in 2026, while the second round now targets 15 additional drugs scheduled for reduced pricing in 2027.

Federal officials say the selected medications accounted for roughly $42.5 billion in Medicare Part D spending during 2024 alone. About 5.3 million Medicare beneficiaries used these medications last year, making them some of the costliest and most widely used drugs in the program. CMS estimates the new negotiated pricing could save Medicare beneficiaries hundreds of millions in out-of-pocket expenses annually.

Weight-Loss Drugs Are Becoming a Major Medicare Battleground

One reason the latest Medicare drug negotiations are attracting so much attention is the inclusion of GLP-1 medications. Ozempic, Wegovy, and Rybelsus (all semaglutide-based drugs produced by Novo Nordisk) are among the most expensive and fastest-growing medications in Medicare spending.

In 2024 alone, Medicare reportedly spent more than $15 billion on these drugs for approximately 2.3 million beneficiaries. CMS says negotiated prices for these medications could reduce costs dramatically, with some reports showing potential discounts exceeding 70% compared to previous pricing.

The debate surrounding these drugs has intensified because many retirees view obesity treatment as essential healthcare, while critics argue widespread GLP-1 coverage could place enormous long-term financial strain on Medicare.

Seniors Could See Real Savings at the Pharmacy Counter

For retirees living on fixed incomes, even moderate prescription savings can make a major difference. CMS estimates the second round of Medicare drug negotiations could save beneficiaries approximately $685 million in out-of-pocket costs once the negotiated prices officially begin in 2027.

Some of the medications included treat chronic conditions like asthma, COPD, diabetes, cancer, schizophrenia, and autoimmune diseases that require long-term treatment. Seniors who currently ration medications, skip refills, or delay treatment due to cost may finally see some relief if negotiated pricing lowers copays and coinsurance obligations.

The Pharmaceutical Industry Is Still Fighting the Program

Despite public support for lower drug prices, Medicare drug negotiations remain highly controversial within the pharmaceutical industry. Drug manufacturers have filed multiple lawsuits arguing that the negotiations unfairly interfere with free-market pricing and could discourage future research and development.

Some companies claim lower government-negotiated prices may reduce incentives to invest in expensive new treatments for cancer, Alzheimer’s disease, and rare conditions. Others warn that aggressive negotiations could eventually spill into the private insurance market, affecting pricing structures beyond Medicare. So far, however, federal courts have largely allowed the negotiation program to continue while legal challenges move through the system.

More Medications Are Already Scheduled for Future Negotiations

The current round of Medicare drug negotiations is not the end of the program. CMS has already announced plans to continue selecting additional medications each year, including both Medicare Part D prescription drugs and certain physician-administered Part B treatments.

In early 2026, another 15 medications were selected for negotiations that will take effect in 2028. Starting in 2029 and beyond, CMS will be allowed to negotiate prices for up to 20 additional drugs annually.

6. There Are Still Questions About Access and Coverage

While lower negotiated prices sound promising, many seniors remain concerned about whether insurance plans will continue covering all medications equally. Some healthcare analysts worry insurers could respond by tightening formularies, increasing prior authorization requirements, or limiting access to expensive treatments even after negotiated prices take effect.

Weight-loss drugs remain especially controversial because Medicare historically has not broadly covered obesity medications under Part D. CMS recently delayed portions of its BALANCE obesity drug pilot program until 2027 while extending temporary bridge coverage for some beneficiaries. Seniors interested in GLP-1 medications may still face eligibility requirements, physician documentation rules, and varying plan coverage depending on where they live.

Medicare Drug Negotiations Could Reshape Senior Healthcare Costs

The expanding Medicare drug negotiations represent one of the most significant healthcare policy shifts affecting retirees in decades. Lower negotiated prices for 15 more medications, including major weight-loss and diabetes treatments, could reduce financial pressure for millions of older Americans beginning in 2027. At the same time, questions remain about long-term drug access, future insurance restrictions, and how pharmaceutical companies may respond to government pricing pressure. Many seniors are hopeful the program will finally make expensive medications more affordable without sacrificing treatment quality or innovation.

Do you believe Medicare drug negotiations will help retirees afford critical medications, or could the changes create new problems down the road? Share your thoughts in the comments below.